Photo left to right: Johannes Dopfer (SGC-Frankfurt) and Jacob Capener (SGC-UNC).

For over two decades, the Structural Genomics Consortium (SGC) has not only established itself as a global leader in accelerating early drug discovery but has also served as an incubator for the next generation of scientific leaders. While much attention has been given to the groundbreaking publications and awards earned by SGC’s senior scientists, today we spotlight the impact of SGC trainees. These rising stars are supported by a collaborative network of more than 250 scientists globally. Their success across all seven SGC research sites is a testament to their dedication, hard work, and brilliance. Two recent awards earned by SGC trainees underscore this impact.

Johannes Dopfer is a PhD student in Susanne Müller-Knapp’s group at SGC Frankfurt. Recently, Johannes was awarded the 2024 Merck Research Grant in AI for Drug Discovery, providing him with the opportunity to work with AIDDISON™, Merck’s advanced platform integrating artificial intelligence, machine learning, and computational drug design. His project focuses on developing a database for fluorescent tracer molecules-a resource that has the potential to streamline and enhance ligand discovery.

“I am honoured that my work has been recognized. I look forward to using AIDDISON's generative models and screening technology in various hit discovery projects”, shares Johannes.

Another remarkable trainee making an impact is Jacob Capener, a graduate student in Alison Axtman’s group at SGC-UNC. Jacob was recently awarded a fellowship by the PhRMA Foundation, an honour given to only 34 early-career researchers. His project, focused on target validation and therapeutic development for Casein Kinase 1 Gamma, underscores the importance of rigorous scientific inquiry in addressing challenging disease targets.

These accolades are not isolated achievements. They reflect the SGC’s unique ecosystem, where cutting-edge research is driven by the passion and talent of its trainees. As the SGC enters its new research phase of Open Data, it does so with the confidence it will generate not only high-quality data but also high-quality scientists who will shape the future of drug discovery in the years to come.